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Abstract
Background: Antiretroviral treatment (cART) in HIV causes lipoatrophy. We examined predictors of anthropometric
outcomes over 96 weeks in HIV-infected, lipoatrophic adults receiving stable cART randomised to tenofovir-emtricitabine
(TDF-FTC) or abacavir-lamivudine (ABC-3TC) fixed dose combinations.
Methodology/Principal Findings: The STEAL study was a prospective trial of virologically suppressed participants
randomised to either TDF-FTC (n=178) or ABC-3TC (n=179). Anthropometric assessment was conducted at baseline, weeks
48 and 96. The analysis population included those with baseline and week 96 data remaining on randomised therapy.
Distribution of limb fat change was divided into four categories (#0%, .0–10%, .10–20%, .20%). Baseline characteristics
[demographics, medical history, metabolic and cardiovascular biomarkers] were assessed as potential predictors of change
in percent subcutaneous limb fat using linear regression. 303 participants (85% of STEAL population) were included.
Baseline characteristics were: mean (6SD) age 45 (68) years; thymidine analogue nucleoside reverse transcriptase inhibitor
(tNRTI) duration 4 (63) years; limb fat 5.4 (63.0)kg; body mass index 24.7 (63.5) kg/m
2. Mean (SD) limb fat gain to week 48
and 96 was 7.6% (622.4) and 13.2% (627.3), respectively, with no significant difference between groups. 51.5% of all
participants had .10% gain in limb fat. Predictors of greater limb fat gain at week 96 were baseline tNRTI (10.3, p=0.001),
glucose .6 mmol/L (16.1, p=0.04), higher interleukin 6 (IL-6) (2.8, p=0.004) and lower baseline limb fat (3.8–6.4 kg – 11.2;
.6.4 kg – 15.7, p trend,0.001).
Conclusions/Significance: Modest peripheral fat gain occurred with both TDF-FTC and ABC-3TC. Baseline factors associated
with more severe lipodystrophy (lipoatrophy, baseline tNRTI, raised IL6, and glucose) predicted greater limb fat recovery at
96 weeks.
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Fat accumulation and depletion (lipoatrophy) are recognised as
potential complications of antiretroviral therapy in HIV-infected
patients [1,2]. In particular, thymidine analogue nucleoside
reverse transcriptase inhibitors (tNRTIs) and protease inhibitors
are associated with potentially treatment limiting body fat
redistribution manifestations [1–4]. These changes in association
with adverse metabolic sequelae and adipose-related inflammation
(known as lipodystrophy), may also lead to a higher risk of
myocardial infarction [5–7].
In lipodystrophy there is adipocyte damage with an increase in
tissue macrophages and production of inflammatory cytokines [8].
The inflammatory changes are also driven by alterations in
adipocyte secreting hormones, particularly decreased adiponectin
and leptin [9]. The reduced hormonal control results in an up-
regulation of cytokines such as tumour necrosis factor (TNFa) and
interleukin 6 (IL-6). With tNRTI-associated lipoatrophy there is
depletion of adipocytes, causing reduction of adenosine 59-
triphosphate (ATP) production which affects lipid and glucose
metabolism, and eventually leads to apoptosis and reduced fat cell
mass [10].
Switching therapy from tNRTIs to non-thymidine based NRTIs
such as abacavir (ABC) or tenofovir (TDF) has been shown to
gradually reverse lipoatrophy, particularly in the more severe cases
[11–16]. Recent studies have examined switching treatment to a
fixed dose combination of KivexaH (ABC/lamivudine (3TC)) or
TruvadaH (TDF/emtricitabine (FTC)), and reported these com-
binations to have similar efficacy [17,18]. The STEAL study
demonstrated that changing treatment to either ABC-3TC or
TDF-FTC caused a gain in peripheral fat in both treatment
groups [18].
The aim of this study was to examine baseline predictors of limb
fat gain in the STEAL study population.
Methods
Objectives
To examine the predictors of anthropometric outcomes,
assessed objectively via dual energy x-ray absorptiometry (DXA),
in the STEAL study.
Participants
Participants in the STEAL body composition sub-study were
enrolled from the STEAL study clinical trial. The STEAL study
was a 96-week, prospective, controlled trial of participants
randomised to simplify existing NRTI drugs to either: tenofovir
300 mg-emtricitabine 200 mg (TDF-FTC) n=178; or abacavir
600 mg-lamivudine 300 mg (ABC-3TC) n=179. The primary
STEAL study cohort and outcomes have been described [18].
Participants were recruited from 30 clinical sites around Australia.
Description of Procedures or Investigations undertaken
DXA scans were performed at baseline, week 48 and week 96.
Peripheral limb fat was described as absolute mass (kg) and
percentage change from baseline to week 48 and 96. The
distribution of limb fat mass changes at 96 were categorised as:
#0%, .0–10%, .10–20% and .20%.
The baseline covariates that were analysed were: Demo-
graphics – age, gender, ethnicity, body mass index (BMI),
smoking, blood pressure, concomitant medication; HIV and
antiretroviral therapy markers – HIV duration, CDC
category, CD4+ and CD8+ lymphocyte counts, duration of
antiretroviral therapy (cART), use of tNRTI vs non-tNRTI,
non-nucleoside reverse transcriptase inhibitors (NNRTI) vs
protease inhibitors (PI), ABC vs TDF, continue on ABC or TDF
vs switch from NRTI; Body composition – peripheral and
trunk fat; Metabolic markers – total cholesterol, HDL
cholesterol, LDL cholesterol, triglycerides; Glycaemic markers
– glucose, HOMA (calculated assessment of insulin sensitivity),
insulin; Cardiovascular Biomarkers – amyloid P, amyloid A,
c-reactive protein (hsCRP), d-dimer, fibrinogen, soluble P selectin,
vascular cell adhesion protein 1 (VCAM), intercelluIar adhesion
protein 1 (ICAM), cystatin C, interleukin 6 (IL-6) and macrophage
migration inhibitory factor (MIF-1). Information on methodology
and coefficient of variation details for the assays used has been
previously described [19].
Ethics
The study was approved by each site’s Research Ethics
Committee (30 sites) and was registered at Clinicaltrials.gov
(NCT00192634). Written informed consent was obtained from all
participants in the sub-study.
Statistical methods
The analysis was conducted on a per-protocol population
defined by participants that had data from baseline and week 96
DXA scans and who remained on their randomised allocated
treatment.
The percent change in limb fat mass was the primary endpoint
and was compared by treatment arm (ABC-FTC vs TDF-3TC)
using the T-test. Percent change in limb fat mass was also
categorised into four groups: limb fat gain of #0%; 0.1–10%;
10.1–20%; and .20%. The distribution of participants in these
categories according to treatment arm was compared using the
Chi squared test.
The association between baseline covariates and percent change
in subcutaneous limb fat from baseline to week 96 were analysed
using linear regression. Multivariate models were built using
forward stepwise methods. Predictors which achieved a p value
,0.1 in univariate analysis were assessed for inclusion in the
multivariate model. The final model was checked using backward
elimination (data not shown). Baseline predictors were categorised
(except for DXA) as previously described in the primary STEAL
analysis and cardiovascular biomarker papers [18,19].
Logistic regression was used to examined the relationship
between the baseline characteristics and the greatest fat gain
(.20% category) in the cohort.
Results
The two randomised arms were well matched (Table 1) in
regards to baseline characteristics, except the ABC-3TC treatment
arm had a higher proportion of smokers then TDF-3TC (40 vs
29%). The mean baseline percent limb fat mass was 17.2 and
17.3%, ABC-3TC and TDF-FTC, respectively. This equates to an
average baseline limb fat mass (SD) across the cohort of 5.4 (3.0)
kg. Baseline characteristics for the per protocol population did not
differ from those of the intention to treat population (data not
shown).
The mean change in peripheral fat over 96 weeks was similar
between treatment arms (p=0.775). There was a 14.1% (5.9 kg)
and 12.3% (6.0 kg) gain in peripheral fat for the ABC-3TC and
TDF-FTC groups, respectively. The participants in both the ABC-
3TC and TDF-FTC arms significantly increased limb fat mass
over 96 weeks (p,0.001). The observed peripheral fat gain was
clinically moderate with patients remaining technically ‘‘lipoatro-
phic’’. Mean (SD) percent gain in limb fat mass for the entire
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13.2% (27.3), respectively (see Figure S1). This is equivalent to
an average peripheral fat gain of 224 g at week 48 and 487 g at
week 96.
There was no significant difference (p=0.493) between the
treatment arms when comparing the proportion of percent fat
change assessed using the four categories (Table 2). Within the
entire cohort 34% of participants had no gain in peripheral limb
fat. Fifty-one percent of participants had .10% gain in limb fat
mass; ABC-3TC (52%) and TDF-FTC (51%), and 35% had
.20% gain; ABC-3TC (37%) and TDF-FTC (33%).
Covariates associated with the percent increase in peripheral fat
mass over 96 weeks on univariable analysis are summarised in
Table 3. The multivariate linear regression analysis demonstrated
that the baseline covariates that were significantly and positively
associated with greater limb fat gain were baseline thymidine
nucleoside therapy (coefficient 10.3, p=0.001), fasting glucose
.6 mmol/L (coefficient 16.1, p=0.04), higher IL-6 (coefficient
2.8, p=0.004) and lower baseline peripheral limb fat (3.8–6.4 kg -
coefficient 11.2; .6.4 kg - coefficient 15.7, p trend,0.001).
Baseline use of tenofovir or abacavir did not predict fat gain. The
adjusted R squared for this model was 0.15.
The multivariate logistic analysis of the baseline predictors of
peripheral fat gain in the participants (35% of cohort) that
experienced .20% gain were prior tNRTI use (OR 2.2,
p=0.001) and lower peripheral fat (OR 0.42, p=0.06).
Discussion
In previous studies various markers have been investigated to
predict the development of lipoatrophy [8–10], however very few
covariates have been tested as predictors of fat gain associated with
reversal of lipoatrophy [11]. This study demonstrated that similar
fat mass gains were evident with both TDF-3TC and ABC-FTC in
virologically stable, NRTI pre-treated HIV positive patients. At
baseline the average limb fat mass across the cohort was 5.4 kg,
which corresponds to a mildly lipodystrophic population. More
than 50% of participants gained at least 10% peripheral body fat
during the 96 week follow-up. In this analysis we identified four
covariates that were independent predictors of greater limb fat
gain following the switch to either treatment arm: baseline
regimen containing a tNRTI, lower peripheral fat, impaired
fasting glucose (.6 mmol/L), and higher IL-6. The composite
model including these variables explained 15% of the observed
changes in body fat over 96 weeks.
Antiretroviral switch studies have previously demonstrated a
gain in limb fat after switching from tNRTIs to ABC [11–13].
Martin et al. demonstrated a 2.5 times greater increase in limb fat
mass when patients on an tNRTI were switched to ABC (1.26 kg)
treatment compared to zidovudine or stavudine (0.49 kg) over 104
weeks [11]. McComsey et al. reported a 22% and 18% increase in
arm and leg fat respectively, after switching from stavudine to
ABC [12]. Similarly, studies examining switching therapy from
tNRTI to TDF have demonstrated increases in total fat mass by
21% [14] and limb fat mass of 0.38 kg [15]. One other study
compared switching to either TDF or ABC and reported similar
limb fat gain in both treatment arms over 48 weeks, increasing by
0.33 kg (TDF) and 0.48 kg (ABC) [16]. Therefore, the limb fat
increase reported in the STEAL study is comparable to previous
studies.
Reported predictors for the development of lipoatrophy include
increased age, being white race, increased duration of HIV
infection, pre-treatment low nadir CD4+ T lymphocyte count and
high plasma HIV RNA load, previous AIDS-defining illness,
hepatitis C co-infection, use of a tNRTI (particularly stavudine),
increased duration of NRTI therapy, adherence to cART, and
TNFa polymorphism 238 G/A [3,20–23]. Only one previous
study has assessed predictors of the reversal of lipoatrophy and
found baseline BMI to be associated with greater fat gain after
switching from tNRTIs to ABC [11].
We have found that baseline tNRTI usage and low peripheral
limb fat were strongly correlated with greater limb fat gain over 96
weeks. Therefore, those with more severe lipoatrophy, probably
Table 1. Baseline characteristics for HIV participants
randomised to ABC-3TC or TDF-FTC (n=357).
Baseline Characteristic ABC-3TC TDF-FTC
Age (years) 46694 4 68
Male (%) 98 97
Ethnicity - white (%) 86 86
Body Mass Index (kg/m
2) 24.763.5 24.863.6
HIV duration (years) 10661 0 66
CD4+ count (cells/mm
3) 6276306 5996257
Peripheral fat (%) 17.2 17.4
Trunk fat (%) 25.7 25.6
Current smoker (%) 40 29
Prior Abacavir (%) 20 21
Prior Tenofovir (%) 30 30
Prior Protease Inhibitor (%) 24 23
hs C-Reactive Protein (mg/L) 5.8621.3 3.867.4
Interleukin-6 (pg/mL) 2.262.0 1.961.4
Amyloid P (ng/mL) 2006144 2086152
Amyloid A (ng/mL) 706109 676106
MIF-1 (pg/mL)** 290163109 280162979
D-Dimer (ngFEU/mL) 2596345 2176205
Fibrinogen (g/L) 2.860.8 2.760.7
P-selectin (ng/mL) 118674 119679
VCAM (ng/mL)*** 3926201 4246223
ICAM (ng/mL)*** 149683 166698
Cystatin C (mg/L) 0.860.1 0.860.1
*Results are expressed as mean 6 SD or %.
**MIF-1=macrophage migration inhibitory factor 1.
***VCAM=vascular cell adhesion molecule; ICAM=intercellular adhesion
molecule.
doi:10.1371/journal.pone.0026885.t001
Table 2. Percent change in peripheral limb fat mass from
baseline to week 96 expressed as quartile categories, based
on randomised arm (n=303).
Randomised Arm #0% .0–10% .10–20% .20%
TDF-FTC (n)* 55 21 28 52
ABC-3TC (n)* 49 22 21 55
Total n (%) 104 (34) 43 (14) 49 (16) 107 (35)
*TDF-FTC=tenofovir - emtricitabine; ABC-3TC + abacavir – lamivudine.
*p value comparing arms over 96 weeks p=0.493.
doi:10.1371/journal.pone.0026885.t002
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limb fat after switching to ABC or TDF. This could be due to a
causal link or could simply be a regression to the mean effect: for
example those with less fat at baseline are more likely to gain fat
throughout the study; and vice versa those with higher baseline
limb fat did not have lipoatrophy and therefore experienced no
limb fat gain.
We also found that impaired glucose metabolism (impaired
fasting glucose) at baseline predicted greater fat gain. These results
suggest there may be an indirect effect of NRTIs on glucose
metabolism via the adipose tissue changes caused by NRTIs [24].
However, insulin resistance, as measured indirectly by HOMA or
insulin levels did not. Therefore, these results may also be a result
of a type-2 error.
Adipose tissue has been shown to produce inflammatory
cytokines, such as C-reactive protein and IL-6 [25]. Some studies
demonstrated high IL-6 to be correlated with limb fat in HIV
patients with lipodystrophy [26,27], whereas others have only
demonstrated the same in HIV positive patients compared with
controls, not those with lipodystrophy [28]. IL-6 mRNA
expression has also been shown to increase in peripheral
adipocytes in HIV treated participants with lipodystrophy [8].
The finding in this study that higher IL-6 levels at baseline was
associated with greater fat gain over 96 weeks, is consistent with
results from these previous studies suggesting that high IL-6 may
represent those participants with lipodystrophy at baseline. This
finding also reinforces the observation that there are immunolog-
ical abnormalities that associate with lipodystrophy.
Limitations
Limitations of this study relate to the inclusion of a HIV
population that is not representative of the wider HIV interna-
tional community i.e. participants were predominantly Caucasian
men recruited within Australia, with well controlled viraemia. In
addition, 20% and 30% of our participants had previously been
exposed to abacavir and tenofovir, respectively. Therefore these
data cannot be generalised beyond similar populations. Stratifica-
tion was conducted on previous NRTIs to control for this
confounder. There was a low predictive value (15%) of the
regression equation suggesting that factors other than those
measured may play an important role in changes in peripheral
fat. The characteristic with the strongest association with change
in peripheral fat was baseline limb fat which may suggest a
regression to the mean affect.
This study shows that changing to either ABC or TDF is
associated with partial, but probably limited, reversal of lipoatro-
phy over 96 weeks. The fat gain may be predicted by baseline
tNRTI, low peripheral fat, impaired glucose metabolism and high
IL-6. These factors associated with predicting limb fat recovery
could represent the patients with severe lipodystrophy and the
associated inflammatory response. This may also infer a simple
regression to the mean effect for patients with more severe
lipodystrophy. Further studies into biomarkers should be conduct-
ed to assess prediction models of fat gain, most importantly those
that are associated with bone and body composition.
Supporting Information
Figure S1 Absolute and percentage change from base-
line in peripheral limb fat mass to week 48 and 96 for
the entire cohort of STEAL participants (ABC-3TC and
TDF-FTC) n=303. *p,0.001 of change from baseline to week
96.
(TIF)
Table 3. Baseline covariates assessed in the multivariate model of percent change in peripheral limb fat mass at 96 weeks for HIV
participants randomised to ABC-3TC or TDF-FTC (n=303).
Baseline Variable Categories Univariate Analysis Multivariate Analysis
Coefficient Lower 95%CI
Upper
95%CI P Coefficient
Lower
95%CI
Upper
95%CI P
On tNRTI* 12.4 6.3 18.5 ,0.0001 10.3 4.4 16.2 0.001
tNRTI duration* 0.1 0.04 0.2 0.003 20.03 20.1 0.1 0.451
Stratification Abacavir (reference group) 0.016 0.071
Tenofovir 4.3 24.6 13.2 7.9 20.7 16.5
Other 11.0 3.0 19.1
Interleukin-6 3.3 1.2 5.3 0.002 2.8 0.9 4.8 0.004
Total Cholesterol (mmol/L) #5.5 (reference group) 0.039 0.074
.5.5 26.7 213.1 0.4 25.5 211.6 0.5
Impaired fasting glucose/
diabetes (mmol/L)
#6 (reference group) 0.067 0.040
.6 15.4 21.1 31.8 16.1 0.7 31.5
Peripheral Fat (kg) ,3.8 (reference group) ,0.001 ,0.001
3.8 to 6.4 210.9 218.2 23.7 211.2 218.3 24.1
.6.4 217.5 224.8 210.2 215.7 222.8 28.6
Trunk fat (kg) ,7.99 (reference group) 0.010 0.869
7.99 to 11.51 25.2 212.6 2.3 20.3 27.8 7.2
.11.51 29.9 217.4 22.4 20.8 29.8 8.3
*tNRTI=thymidine nucleoside reverse transcriptase inhibitors.
doi:10.1371/journal.pone.0026885.t003
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